Brokerages Set Aytu BioPharma Inc. (NASDAQ:AYTU) PT at $9.17

Aytu BioPharma Inc. (NASDAQ:AYTU) has received a consensus rating of “Hold” from the five ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $9.1667.

Several research analysts have recently issued reports on AYTU shares. Zacks Research raised Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research report on Monday, November 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Tuesday, October 14th. Maxim Group dropped their price target on shares of Aytu BioPharma from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, September 25th. Wall Street Zen cut shares of Aytu BioPharma from a “buy” rating to a “hold” rating in a report on Friday, September 26th. Finally, Ascendiant Capital Markets upped their target price on shares of Aytu BioPharma from $12.00 to $12.50 and gave the company a “buy” rating in a report on Thursday, September 25th.

Aytu BioPharma Trading Down 0.9%

NASDAQ AYTU opened at $2.22 on Wednesday. Aytu BioPharma has a 52 week low of $0.95 and a 52 week high of $2.82. The firm has a 50 day moving average of $2.15 and a two-hundred day moving average of $2.19. The company has a quick ratio of 1.08, a current ratio of 1.23 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $22.62 million, a PE ratio of -0.73 and a beta of 0.28.

Aytu BioPharma (NASDAQ:AYTU) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02). The firm had revenue of $13.89 million for the quarter, compared to analysts’ expectations of $17.92 million. Aytu BioPharma had a positive return on equity of 17.86% and a negative net margin of 20.52%.

Hedge Funds Weigh In On Aytu BioPharma

Several hedge funds have recently made changes to their positions in the company. FNY Investment Advisers LLC purchased a new stake in shares of Aytu BioPharma in the 2nd quarter valued at about $78,000. Stonepine Capital Management LLC grew its stake in Aytu BioPharma by 13.8% during the 1st quarter. Stonepine Capital Management LLC now owns 463,721 shares of the company’s stock worth $556,000 after buying an additional 56,172 shares during the last quarter. Kanen Wealth Management LLC acquired a new position in Aytu BioPharma during the second quarter worth approximately $1,250,000. AWM Investment Company Inc. purchased a new stake in Aytu BioPharma in the second quarter valued at approximately $1,351,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Aytu BioPharma in the third quarter valued at approximately $117,000. Hedge funds and other institutional investors own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.